Correlation Engine 2.0
Clear Search sequence regions

  • cisplatin (1)
  • dogs (7)
  • humans (1)
  • oxaliplatin (7)
  • patients (1)
  • plasma (2)
  • platinum (2)
  • Sizes of these terms reflect their relevance to your search.

    Oxaliplatin is more potent than cisplatin, lacks cross-resistance to other platinum agents, and has a favorable toxicity profile. This study's objective was to define the maximally tolerated dose and the dose-limiting toxicity (DLT) of oxaliplatin in cancer-bearing dogs. This was a prospective, single-patient-cohort, dose-escalation study of oxaliplatin in client-owned dogs with confirmed, spontaneous malignancy. A single infusion was administered; the starting dose was 50 mg/m2, with 10 mg/m2 escalation-increments if no DLT was documented, up to a maximum dose of 140 mg/m2. Plasma total platinum was measured at multiple timepoints and patients were monitored weekly. Ten dogs were enrolled in single-patient-cohort treatment levels up to the maximum level of 140 mg/m2. There were no DLTs, and the maximally tolerated dose was not determined. The area under the curve0-7 days for 100-140 mg/m2 ranged from 77,850 to 82,860 ng/mL × hr; the area under the curve0-4 hr for 50-140 mg/m2 was linear with dose (r2 = 0.639, P = .0055). The data suggest a single infusion of oxaliplatin is well tolerated in cancer-bearing dogs up to 140 mg/m2. There was good correlation between exposure and dose, while achieving plasma levels similar to therapeutic levels documented in humans.


    Shawna Klahn, Nikolaos Dervisis, Daniel L Gustafson, Jonathan Abbott. Dose-Escalation and Pharmacokinetic Study Following a Single Dose of Oxaliplatin in Cancer-Bearing Dogs. Journal of the American Animal Hospital Association. 2020 Jul/Aug;56(4):206-214

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32412339

    View Full Text